Histological Typing of Urinary Bladder Tumours

Mostofi, F. K.; Davis, Charlotte; Ia, Sesterhenn; Sobin, Leslie H.

doi:10.1007/978-3-642-59871-5

Cited by 345 publications

(337 citation statements)

References 0 publications

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…Sample pathology reports from a uropathologist were used to obtain the cumulative data. All bladder tumors were classified using TNM 2002 13 and World Health Organization (1973) 14 classifications.…”

Section: Methodsmentioning

confidence: 99%

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Palou

Rodríguez-Rubio

Millán

et al. 2009

Urology

View full text Add to dashboard Cite

OBJECTIVESTo evaluate the risk factors for disease progression in the frequent subgroup of Stage T1G2 (World Health Organization 1973) bladder tumors using an analysis of a large cohort of patients with Stage T1G2 disease. METHODSA cohort of 616 patients with Stage T1G2 were treated with transurethral resection and random bladder biopsies. The mean follow-up was 4.2 years. Univariate and multivariate analyses were done using Cox regression analysis. The independent variables were multiplicity, association with carcinoma in situ (CIS), tumor size, tumor recurrence at 3 or 6 months, tumor grade, and association with CIS at first recurrence. The dependent variable was progression to muscleinvasive disease. RESULTSProgression to muscle-invasive disease was identified in 28 of the 616 patients (4.5%). On multivariate analysis, when considering recurrence at 3 months, this factor was the principal prognostic factor, with a relative risk of 4.0 (95% confidence interval 1.2-13.3), followed by the presence of high-grade disease or CIS at first recurrence (relative risk 2.8, 95% confidence interval 1.3-5.8) and CIS associated with the primary tumor (relative risk 1.8, 95% confidence interval 1.1-2.9). When considering recurrence at 6 months, more prognostic factors were involved for progression, including as multiple tumors, CIS associated with the primary tumor, recurrence at 6 months, and the presence of high-grade disease or CIS at the first recurrence. CONCLUSIONSIn primary urothelial T1G2 bladder cancer, recurrence at 3 months was the main prognostic factor related to progression. Additional factors were the association of CIS with the primary tumor and the presence of high-grade disease and/or CIS at first recurrence. UROLOGY 73: 1313UROLOGY 73: -1317UROLOGY 73: , 2009

show abstract

Section: Methodsmentioning

confidence: 99%

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Palou

Rodríguez-Rubio

Millán

et al. 2009

Urology

View full text Add to dashboard Cite

show abstract

“…All histological sections were reviewed by a pathologist and material adequate for immunohistochemistry was selected. Histological typing and grading was performed according to the WHO classification (Mostofi, 1973). The tumour stage was determined according to the UICC recommendations (Hermanek and Sobin, 1992).…”

Section: Methodsmentioning

confidence: 99%

Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma

Clasen

Schulz²,

Gerharz³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

No mutations were observed in the WAF1/p21 gene in these tumours, but two were heterozygous for the codon 31 polymorphism. These data indicate that p21 is frequently expressed in superficial, well differentiated urothelial carcinomas, but less often in muscle-invasive urothelial carcinomas, irrespective of their p53 status. The expression of p21 and its prevalence in low-stage tumours may reflect residual growth-regulatory influences potentially impeding but not necessarily inhibiting tumour development.

show abstract

“…26 Either the 1973 126,127 or 2004 126,127 WHO grading system may be used for this purpose. Laboratories accredited by the College of American Pathologists are required to use the CAP cancer reporting guidelines.…”

Section: Histological Gradingmentioning

confidence: 99%